Literature DB >> 24556352

Patient-reported and actionable safety events in CKD.

Jennifer S Ginsberg1, Min Zhan2, Clarissa J Diamantidis1, Corinne Woods3, Jingjing Chen1, Jeffrey C Fink4.   

Abstract

Patients with CKD are at high risk for adverse safety events because of the complexity of their care and impaired renal function. Using data from our observational study of predialysis patients with CKD enrolled in the Safe Kidney Care study, we estimated the baseline frequency of adverse safety events and determined to what extent these events co-occur. We examined patient-reported adverse safety incidents (class I) and actionable safety findings (class II), conditioned on participant use of drugs that might cause such an event, and we used association analysis as a data-mining technique to identify co-occurrences of these events. Of 267 participants, 185 (69.3%) had at least one class I or II event, 102 (38.2%) had more than one event, and 48 (18.0%) had at least one event from both classes. The adjusted conditional rates of class I and class II events ranged from 2.9 to 57.6 per 100 patients and from 2.2 to 8.3 per 100 patients, respectively. The most common conditional class I and II events were patient-reported hypoglycemia and hyperkalemia (serum potassium>5.5 mEq/L), respectively. Reporting of hypoglycemia (in patients with diabetes) and falling or severe dizziness (in patients without diabetes) were most frequently paired with other adverse safety events. We conclude that adverse safety events are common and varied in CKD, with frequent association between disparate events. Further work is needed to define the CKD "safety phenotype" and identify patients at highest risk for adverse safety events.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Keywords:  chronic kidney disease; data mining; patient safety

Mesh:

Year:  2014        PMID: 24556352      PMCID: PMC4073439          DOI: 10.1681/ASN.2013090921

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

1.  Mining gene expression databases for association rules.

Authors:  Chad Creighton; Samir Hanash
Journal:  Bioinformatics       Date:  2003-01       Impact factor: 6.937

2.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

Authors:  Tilman B Drüeke; Francesco Locatelli; Naomi Clyne; Kai-Uwe Eckardt; Iain C Macdougall; Dimitrios Tsakiris; Hans-Ulrich Burger; Armin Scherhag
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

Review 3.  Drug-induced hyperkalemia: old culprits and new offenders.

Authors:  M A Perazella
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

4.  Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.

Authors:  Keith Norris; Jacque Bourgoigne; Jennifer Gassman; Lee Hebert; John Middleton; Robert A Phillips; Otelio Randall; Stephen Rostand; Susan Sherer; Robert D Toto; Jackson T Wright; Xuelei Wang; Tom Greene; Lawrence J Appel; Julia Lewis
Journal:  Am J Kidney Dis       Date:  2006-11       Impact factor: 8.860

5.  Five years after To Err Is Human: what have we learned?

Authors:  Lucian L Leape; Donald M Berwick
Journal:  JAMA       Date:  2005-05-18       Impact factor: 56.272

6.  Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients.

Authors:  Andrea Corsonello; Claudio Pedone; Francesco Corica; Chiara Mussi; Pierugo Carbonin; Raffaele Antonelli Incalzi
Journal:  Arch Intern Med       Date:  2005-04-11

7.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

8.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

9.  Anaphylaxis: clinical patterns, mediator release, and severity.

Authors:  Simon G A Brown; Shelley F Stone; Daniel M Fatovich; Sally A Burrows; Anna Holdgate; Antonio Celenza; Adam Coulson; Leanne Hartnett; Yusuf Nagree; Claire Cotterell; Geoffrey K Isbister
Journal:  J Allergy Clin Immunol       Date:  2013-08-01       Impact factor: 10.793

10.  Mining frequent patterns for AMP-activated protein kinase regulation on skeletal muscle.

Authors:  Qingfeng Chen; Yi-Ping Phoebe Chen
Journal:  BMC Bioinformatics       Date:  2006-08-30       Impact factor: 3.169

View more
  15 in total

1.  Usability Testing of a Sick-Day Protocol in CKD.

Authors:  Rebecca M Doerfler; Clarissa J Diamantidis; Lee-Ann Wagner; Beth M Scism; Monifa Vaughn-Cooke; Wanda J Fink; Thomas Blakeman; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-13       Impact factor: 8.237

2.  Self-reported Medication Adherence and Adverse Patient Safety Events in CKD.

Authors:  Kailin L Hsu; Jeffrey C Fink; Jennifer S Ginsberg; Marni Yoffe; Min Zhan; Wanda Fink; Corinne M Woods; Clarissa J Diamantidis
Journal:  Am J Kidney Dis       Date:  2015-05-13       Impact factor: 8.860

Review 3.  Maintaining safety in the dialysis facility.

Authors:  Alan S Kliger
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

Review 4.  Telemedicine to Promote Patient Safety: Use of Phone-Based Interactive Voice-Response System to Reduce Adverse Safety Events in Pre-dialysis CKD.

Authors:  Shoshana Weiner; Jeffery C Fink
Journal:  Adv Chronic Kidney Dis       Date:  2017-01       Impact factor: 3.620

5.  Chronic pain and analgesic use in CKD: implications for patient safety.

Authors:  Juliana Wu; Jennifer S Ginsberg; Min Zhan; Clarissa J Diamantidis; Jingjing Chen; Corinne Woods; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-20       Impact factor: 8.237

6.  Remote Usability Testing and Satisfaction with a Mobile Health Medication Inquiry System in CKD.

Authors:  Clarissa J Diamantidis; Jennifer S Ginsberg; Marni Yoffe; Lisa Lucas; Divya Prakash; Saurabh Aggarwal; Wanda Fink; Stefan Becker; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-28       Impact factor: 8.237

7.  Adverse Drug Reactions in Patients with CKD.

Authors:  Solène M Laville; Valérie Gras-Champel; Julien Moragny; Marie Metzger; Christian Jacquelinet; Christian Combe; Denis Fouque; Maurice Laville; Luc Frimat; Bruce M Robinson; Bénédicte Stengel; Ziad A Massy; Sophie Liabeuf
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-01       Impact factor: 8.237

8.  Insulin for the treatment of hyperkalemia: a double-edged sword?

Authors:  Tingting Li; Anitha Vijayan
Journal:  Clin Kidney J       Date:  2014-06

9.  Patient-Reported Safety Events in Chronic Kidney Disease Recorded With an Interactive Voice-Inquiry Dial-Response System: Monthly Report Analysis.

Authors:  Jeffrey C Fink; Rebecca M Doerfler; Marni R Yoffe; Clarissa J Diamantidis; Jacob B Blumenthal; Tariq Siddiqui; James F Gardner; Soren Snitker; Min Zhan
Journal:  J Med Internet Res       Date:  2016-05-26       Impact factor: 5.428

Review 10.  GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.

Authors:  José Luis Górriz; María José Soler; Juan F Navarro-González; Clara García-Carro; María Jesús Puchades; Luis D'Marco; Alberto Martínez Castelao; Beatriz Fernández-Fernández; Alberto Ortiz; Carmen Górriz-Zambrano; Jorge Navarro-Pérez; Juan José Gorgojo-Martinez
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.